OncoZenge AB (publ) (STO:ONCOZ)

Market Cap	88.79M
Revenue (ttm)	2.71M
Net Income (ttm)	-6.27M
Shares Out	11.71M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,991
Average Volume	78,726
Open	6.45
Previous Close	6.38
Day's Range	6.38 - 7.59
52-Week Range	3.15 - 12.10
Beta	1.42
RSI	65.02
Earnings Date	Aug 8, 2025

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCOZ

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.